Describes in detail the main neuroimaging findings in various primary psychotic disorders
Identifies findings common to and specific for each disorder
Highlights potential translational aspects of research in the field
About the Author: Silvana Galderisi is full professor of Psychiatry and Director of the Training School in Psychiatry at the University of Campania Luigi Vanvitelli. She is the Director of the Emergency Unit of the Department of Mental Health of the same University; Coordinator of the Outpatient Unit for Anxiety and Psychotic Disorders and of the Rehabilitation Program for severe mental disorders of the same Department. She is President of the European Psychiatric Association (EPA), Chairperson of the Neuroimaging Section of the World Psychiatric Association (WPA), of the EPA Schizophrenia Section, and of the European College of NeuroPsychopharmacology (ECNP) Schizophrenia Network. She is founding member and member of the Board of Directors of the European Group for Research in Schizophrenia; board member of the Schizophrenia International Research Society (SIRS), of the European Scientific Association on Schizophrenia (ESAS), of the Italian Society for Psychopathology and Italian Society of Biological Psychiatry. She has also served as President of the International Society for Brain Electromagnetic Topography and President of the EEG & Clinical Neuroscience Society. She is Honorary Member of the World Psychiatric Association-WPA, and International Distinguished Fellow of the American Psychiatric Association-APA.
She is author/coauthor of more than 200 publications, in national and international journals and books, and member of the Editorial Boards of several international psychiatric journals.
Dr. DeLisi is currently an Attending Psychiatrist in the VA Boston Healthcare System and Professor of Psychiatry at Harvard Medical School. In addition, she has been Editor-in-Chief and co-founder of the Schizophrenia Research journal from the mid 1980's until 2017. Beginning January, 2019 she will be editor-in-chief of the journal Psychiatry Research. She was secretary, as well as co-founder, of two professional organizations: The Schizophrenia International Research Society (SIRS) and The International Society of Psychiatric Genetics (ISPG) and is currently president of SIRS.
Dr DeLisi was the first to conduct a longitudinal controlled MRI study that showed progressive brain change in schizophrenia and was a pioneer in developing an international collaboration for ascertainment of families with multiple members having schizophrenia to participate in molecular genetic studies. From 2001 through 2008 she was professor at New York University School of Medicine and Associate Director of the brain imaging division at The Nathan Kline Institute for Psychiatric Research where she contributed several studies on anomalies of language processing in people at high risk for schizophrenia. She moved to her current position in the Boston area in January 2009 where she continues to focus her research on biological markers for high risk for schizophrenia and the effects of marijuana on adolescents.
Dr DeLisi edited and authored over 300 books and manuscripts and aside from editing her own journal, serves on the editorial board of several other journals.
Stefan Borgwardt is a Professor of Neuropsychiatry in the Department of Psychiatry, University of Basel, Switzerland. He is Head Physician at the Psychiatric University Hospital (UPK), Basel, where he also heads the Neuropsychiatry and Brain Imaging research group. Dr. Borgwardt graduated from the Charité Medical School, Berlin and trained in psychiatric practice and research methodology in Basel, subsequently becoming a clinical research fellow at the Institute of Psychiatry, King´s College London, where he is now a Visiting Professor. He is also Secretary of the Section of Neuroimaging of the World Psychiatric Association (WPA). His research interests include structural and functional neuroimaging, pharmacological neuroimaging methods, and neurocognitive and genetic mechanisms in schizophrenia.
